July 22, 2011PLoS ONEOpen Access

Improvement of Cardiac Function in Mouse Myocardial Infarction after Transplantation of Epigenetically-Modified Bone Marrow Progenitor Cells

Q: What is the clinical evidence from this study?

Population: Acute myocardial infarction (n=30). Intervention: Epigenetically-modified bone marrow progenitor cells (eiBPCs) vs. Unmodified bone marrow progenitor cells or saline. Primary outcome: Left ventricular function (LV diastolic dimension and LV fractional shortening) (p=<0.05).

View Full Paper

Ask AI

Bookmark

Key result

Transplantation of epigenetically-modified bone marrow progenitor cells into infarcted mouse hearts significantly improved left ventricular function and decreased myocardial fibrosis compared to unmodified cells or saline.

Why the study?

Does transplantation of epigenetically-modified bone marrow progenitor cells improve left ventricular function in a mouse model of acute myocardial infarction?

Population

Mouse model of acute myocardial infarction (AMI)

Comparison

Intra-myocardial injection of bone marrow… vs Untreated bone marrow progenitor cells

Design

Preclinical

Authors

JRJohnson RajasinghSRM Institute of Science and Technology JTJayakumar ThangavelUniversity of Kansas Medical Center MSMohammad R. SiddiquiNorthwestern University

Discussion

Member takes

Implication

Does not support clinical use; leaves open whether epigenetic modification enhances cell therapy efficacy in human MI.

Structured PICO

Does transplantation of epigenetically-modified bone marrow progenitor cells improve left ventricular function in a mouse model of acute myocardial infarction?

Population

30 8-week-old male mice with induced acute myocardial infarction treated with intramyocardial injection of epigenetically-modified bone marrow progenitor cells, unmodified cells, or saline, followed for 4 weeks.

Intervention

Intra-myocardial injection of bone marrow progenitor cells (BPCs) treated with chromatin modifying agents Trichostatin A (TSA) and 5Aza-2-deoxycytidine (Aza)

Comparator

Untreated bone marrow progenitor cells

Outcome

Left ventricular functionsurrogate

Main Result

p-value: p=<0.05

Epigenetic modification of bone marrow progenitor cells with chromatin modifying agents enhances their differentiation potential and improves cardiac function post-myocardial infarction in mice.

Limitations

Did not examine the in situ electrophysiological properties of the regenerated cardiomyocytes.
Only up to 5% of transplanted cells were retained in the myocardium at day 28.
Improvement in cardiac function could also be partially due to secretion of factors by transplanted cells or host tissue.

Cite This Study

Rajasingh et al. (2011) studied Acute myocardial infarction (n=30). Epigenetically-modified bone marrow progenitor cells (eiBPCs) vs. Unmodified bone marrow progenitor cells or saline was evaluated on Left ventricular function (LV diastolic dimension and LV fractional shortening) (p=<0.05). Transplantation of epigenetically-modified bone marrow progenitor cells into infarcted mouse hearts significantly improved left ventricular function and decreased myocardial fibrosis compared to unmodified cells or saline.

synapsesocial.com/papers/6a8830039fc8a8114e4a6912 https://doi.org/10.1371/journal.pone.0022550

View Full Paper

Ask AI

Bookmark

Improvement of Cardiac Function in Mouse Myocardial Infarction after Transplantation of Epigenetically-Modified Bone Marrow Progenitor Cells

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Improvement of Cardiac Function in Mouse Myocardial Infarction after Transplantation of Epigenetically-Modified Bone Marrow Progenitor Cells

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider